Incidence of dizziness and vertigo in Japanese primary care clinic patients with lifestyle-related diseases: an observational study

Masaoki Wada1,2
Taro Takeshima1
Yosikazu Nakamura3
Shoichiro Nagasaka4
Toyomi Kamesaki1
Hiroshi Oki2
Eiji Kajii1

1Division of Community and Family Medicine, Center for Community Medicine, Jichi Medical University, Tochigi, Japan; 2Oki Clinic, Ibaraki, Japan; 3Department of Public Health, Jichi Medical University, Tochigi, Japan; 4Department of Internal Medicine, Division of Endocrinology and Metabolism, Jichi Medical University, Tochigi, Japan

Objective: Dizziness and vertigo are highly prevalent symptoms among patients presenting at primary care clinics, and peripheral vestibular disorder (PVD) is their most frequent cause. However, the incidence of PVD has not been well documented. This study aimed to investigate the incidence of dizziness, vertigo, and PVD among patients presenting at a primary care clinic.

Design: This was an observational study.

Setting and participants: Between November 2011 and March 2013, we observed 393 patients, all at least 20 years old, who had been treated for chronic diseases such as hypertension, dyslipidemia, and diabetes mellitus for at least 6 months at a primary clinic (Oki Clinic) in Japan.

Outcome: The main outcome of interest was new incidence of dizziness, vertigo, and PVD events. During the 1-year follow-up period, the otolaryngologist diagnosed and reported new PVD events.

Results: The mean age of the 393 participants at entry was 65.5 years. Of the study participants, 12.7%, 82.4%, and 92.6% had diabetes mellitus, hypertension, and dyslipidemia, respectively. We followed up all the participants (100%). During the 662.5 person-years of follow-up, 121 cases of dizziness or vertigo (dizziness/vertigo) and 76 cases of PVD were observed. The incidence of dizziness/vertigo and PVD was 194.7 (95% confidence interval: 161.6–232.6) per 1,000 person-years and 115.7 (95% confidence interval: 92.2–142.6) per 1,000 person-years, respectively. There were 61 cases of acute peripheral vestibulopathy, 12 of benign paroxysmal positional vertigo, and three of Meniere’s disease among the 76 PVD patients.

Conclusion: We reported the incidence of dizziness/vertigo among Japanese primary care clinic patients, which was higher than that usually observed in the general population. Furthermore, we described the incidence of PVD and found that it was a major cause of dizziness/vertigo.

Keywords: dizziness, incidence, primary care health, observational study

Introduction

Dizziness and vertigo are among the most common community health symptoms.1,2 They are frequent chief complaints in hospitals,3,4 emergency departments,5 and primary care clinics.6-8 Furthermore, they are known to be associated with declining quality of life and increased functional disability.9,10 Therefore, the social and medical costs of these persistent symptoms need to be considered.8

Prevalence of dizziness/vertigo was examined within the general population and in primary care settings.1,2,10-13 Some previous studies have reported on the frequency of patients who complained of dizziness/vertigo at primary care clinics.7,8 The incidence of dizziness/vertigo was also examined among patients who visited their family physicians.2
The diagnostic management of dizziness/vertigo is challenging for physicians, because they occur as a result of many diseases; however, fatal diseases are not often included in the diagnoses of primary care patients who complain of these conditions. Peripheral vestibular disorder (PVD) is the most frequent cause of dizziness/vertigo. PVD indicates a limited disorder of the cranial nerve VIII and all its distal structures. Patients with PVD demonstrate nystagmus to the contralateral side which is suppressed with visual fixation. Nystagmus improves with gaze toward the lesion and worsens with gaze in the direction opposite to the lesion. PVD is distinguishable from central vestibular disorders and includes acute peripheral vestibulopathy (APV), benign paroxysmal positional vertigo (BPPV), and Meniere’s disease (MD).

The frequency of PVD patients who visit emergency rooms and primary care clinics has been reported in previous studies, and the prevalence of dizziness/vertigo that was suspected to be due to PVD was also examined within the community. However, the diagnosis of PVD in these studies was not objective because it was based on answers to questionnaire surveys. In addition, PVD incidence within primary care settings was unclear.

We followed-up with patients who were being treated at a primary care clinic and investigated the incidence of dizziness/vertigo and PVD using clear diagnostic criteria under the guidance of a professional otorhinolaryngologist.

Method

Study design

This was an observational study.

Participants and setting

Between November 2011 and March 2013, we observed 393 patients who had been treated for chronic diseases, such as hypertension, dyslipidemia, and diabetes mellitus for at least 6 months at a primary care clinic (Oki Clinic). All subjects were at least 20 years old, and we followed each of them for at least 1 year. The Oki Clinic is a primary care clinic that was established in 1981. It is located in Yuki city, in the western part of Ibaraki Prefecture. Three physicians – a board certified otorhinolaryngologist, a board certified neurosurgeon, and a board certified member of the Japanese Society of Internal Medicine – who work at the Oki Clinic were the doctors who followed-up with the participants.

Measurements at baseline

We examined age, sex, smoking status (never, former, or current), Brinkman Index (daily number of cigarettes × years), drinking status (never, occasionally, or current), ethanol intake (g per day), systolic blood pressure (mmHg), diastolic blood pressure (mmHg), total cholesterol, low-density lipoprotein cholesterol (mg/dL), high-density lipoprotein cholesterol (mg/dL), triglycerides (mg/dL), glycosylated hemoglobin (HbA1c; National Glycohemoglobin Standardization Program) (%), and serum creatinine (mg/dL). Dyslipidemia was defined as low-density lipoprotein cholesterol ≥140 mg/dL, high-density lipoprotein cholesterol <40 mg/dL, triglycerides ≥150 mg/dL, total cholesterol ≥220 mg/dL, or use of anti-hyperlipidemic medication. Hypertension was defined as systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or use of anti-hypertensive medication. Diabetes mellitus was defined as fasting plasma glucose ≥126 mg/dL, non-fasting plasma glucose ≥200 mg/dL, HbA1c (National Glycohemoglobin Standardization Program) ≥6.5%, or use of anti-hyperglycemic medication.

Outcome

The main outcomes of interest were new dizziness, vertigo, and new PVD events. During the 1-year follow-up period, the participants who experienced dizziness/vertigo had a medical consultation within a few days after the onset of new dizziness/vertigo, and the board certified otorhinolaryngologist who worked at Oki Clinic diagnosed and reported new PVD events in reference to medical history and clinical views according to the relevant diagnostic guidelines. Dizziness was defined as the sensation of disturbed or impaired spatial orientation without a false or distorted sense of motion, and vertigo was defined as the sensation of self-motion when no self-motion is occurring or the sensation of distorted self-motion during an otherwise normal head movement.

We classified PVD according to the relevant diagnostic guidelines. PVD included APV, BPPV, and MD, and we adopted the following strict diagnostic criteria about these three diseases.

Clinical diagnostic criteria for APV

APV was defined as fulfilling all of the following three criteria: 1) rotatory vertigo lasting longer than 1 minute and being associated with persistent horizontal, spontaneous nystagmus; 2) ataxia; and 3) no sign of cochlear or central nerve involvement.

Clinical diagnostic criteria for BPPV

BPPV was defined as fulfilling all of the following four criteria: 1) vertigo associated with a characteristic mixed torsional and vertical nystagmus provoked by the Dix–Hallpike test; 2) a latency (typically of 1 to 2 seconds) between the completion
of the Dix–Hallpike test and the onset of vertigo and nystagmus; 3) the paroxysmal nature of the provoked vertigo and nystagmus (ie, an increase and then a decline over a period of 10 to 20 seconds); and 4) fatigue (ie, a reduction in vertigo and nystagmus if the Dix–Hallpike test is repeated). \(^{28,29}\)

**Clinical diagnostic criteria for MD**

MD was defined as fulfilling all of the following three criteria: 1) two or more definitive spontaneous episodes of vertigo lasting 20 minutes or longer; 2) audiometrically documented hearing loss on at least one occasion; and 3) tinnitus or aural fullness in the treated ear.\(^{30,31}\)

**Analysis**

All analyses were performed using Stata, version 12.1 (StataCorp LP, College Station, TX, USA). Data are presented as means ± standard deviations and population percentages. To determine the incidence of dizziness and vertigo, we calculated the number of patients who consulted the Oki Clinic otorhinolaryngologist for new dizziness, vertigo, and PVD events. The incidence were calculated per 1,000 person-years. We used the Kaplan–Meier curve to show and estimate the cumulative incidence for the endpoints of new dizziness, vertigo, and PVD.

**Ethics**

This study was approved by the clinical research institutional review board of Jichi Medical University.

**Result**

The baseline characteristics of the 393 study participants are shown in Table 1. The mean age of the participants at entry was 65.5 years, and 33.8% were men. Of the 393 study participants, 12.7%, 82.4%, and 92.6% had diabetes mellitus, hypertension, and dyslipidemia, respectively.

We followed-up with all 393 participants (100%; 393/393) for 633.0 days (median). During the 662.5 person-years of follow-up, there were 121 new events of dizziness/vertigo, and the incidence of dizziness/vertigo was 194.7 (95% confidence interval: 161.6–232.6) per 1,000 person-years. Figure 1 shows the unadjusted cumulative event rates for dizziness and vertigo. There were 42 cases of dizziness and 79 cases of vertigo.

In addition, 76 new PVD (63.0%) events were observed, and the incidence of PVD was 115.7 (95% confidence interval: 92.2–142.6) per 1,000 person-years. Figure 2 shows the cumulative event rates for APV, BPPV, and MD. There were 61 (80.3%) cases of APV, 12 (15.8%) of BPPV, and three (3.9%) of MD among the 76 PVD patients.

**Discussion**

To the best of our knowledge, this is the first investigation of PVD incidence, as identified by a board certified otorhinolaryngologist in a primary care setting. We followed-up with the 393 patients for 633.0 days and identified 121 episodes of dizziness/vertigo. From those assessments, we were able to diagnose the 76 PVD patients (63.0%). In addition, we described the incidence of dizziness/vertigo and PVD: 194.7 per 1,000 person-years and 115.7 per 1,000 person-years, respectively. Our results differ significantly, in some ways, from those of previous studies.

The incidence of dizziness/vertigo in our study was higher than in previous studies. The Dutch National Survey of General Practice 2001 reported that the incidence of dizziness/vertigo was 47.1 per 1,000 person-years among patients aged 65 years or older who consulted their family physicians.\(^2\) On the other hand, the 1-year incidence of dizziness/vertigo assessed through the German National Telephone Health Interview Survey 2003 was reported

**Table 1** Baseline characteristics of the 393 study participants

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>65.5±8.2</td>
</tr>
<tr>
<td>Male sex</td>
<td>133 (33.8)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>50 (12.7)</td>
</tr>
<tr>
<td>Medications</td>
<td>28 (56)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>324 (82.4)</td>
</tr>
<tr>
<td>Medications</td>
<td>320 (98.8)</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>364 (92.6)</td>
</tr>
<tr>
<td>Medications</td>
<td>127 (34.9)</td>
</tr>
<tr>
<td>Brinkman Index</td>
<td>226.9±23.3</td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>285 (72.5)</td>
</tr>
<tr>
<td>Former</td>
<td>59 (15.0)</td>
</tr>
<tr>
<td>Current</td>
<td>49 (12.5)</td>
</tr>
<tr>
<td>Ethanol intake (g/day)</td>
<td>8.47±0.95</td>
</tr>
<tr>
<td>Drinking status</td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>256 (65.1)</td>
</tr>
<tr>
<td>Occasional</td>
<td>41 (10.4)</td>
</tr>
<tr>
<td>Current</td>
<td>96 (24.4)</td>
</tr>
<tr>
<td>Blood pressure (mmHg)</td>
<td></td>
</tr>
<tr>
<td>Systolic</td>
<td>133.0±10.9</td>
</tr>
<tr>
<td>Diastolic</td>
<td>77.1±8.5</td>
</tr>
<tr>
<td>Triglyceride (mg/dL)</td>
<td>168.5±105.4</td>
</tr>
<tr>
<td>Cholesterol (mg/dL)</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>223.1±40.2</td>
</tr>
<tr>
<td>LDL</td>
<td>133.9±33.1</td>
</tr>
<tr>
<td>HDL</td>
<td>56.1±14.9</td>
</tr>
<tr>
<td>Hba1c (NGSP; %)</td>
<td>5.9±0.59</td>
</tr>
<tr>
<td>Cr (mg/dL)</td>
<td>0.69±0.15</td>
</tr>
</tbody>
</table>

Notes: *Plus-minus values are means ± standard deviation. Numerical values depict the frequency number. Numerical values in parentheses depict the proportion (%). Abbreviations: LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; Hba1c, glycosylated hemoglobin; NGSP, National Glycohemoglobin Standardization Program; Cr, serum creatinine.
as being 1.4%.\textsuperscript{18} This may have been due to the different backgrounds of the study populations or the differences in dizziness/vertigo measurements. In our study, the patients were treated as if they had lifestyle-related diseases, so we monitored their dizziness/vertigo more frequently than was done in previous studies. In addition, the patients who may have exhibited dizziness and vertigo because of antihypertensive drugs, diuretic and anxiolytic use are included.

The proportion of PVD (63.0\%) among those who reported dizziness/vertigo in our study was slightly higher than in previous studies.\textsuperscript{8,14,15} In previous reports, dizziness/vertigo was attributed to PVD in 221 out of 503 patients (44\%) and 3,125 out of 9,472 patients (33\%).\textsuperscript{8,15} This might be due to differences in the populations or PVD measurements. In our study, the participants’ ages (mean age: 65.5 years) were older than those in the abovementioned studies (mean ages: 58 and 52.9 years, respectively). However, the proportion of APV (80.2\%) among the 76 PVD patients in our study was similar to the proportion of APV (71.6\%)
assessed by the study of emergency department visits in the National Hospital Ambulatory Medical Care Survey (NHAMCS).\textsuperscript{32}

The participants who complained of dizziness/vertigo were examined by a board certified otorhinolaryngologist in this study; therefore, PVD was detected more precisely. The risk of missing a diagnosis of PVD was reduced. This was one of our study’s main strengths. The other was that we followed-up all the participants. This led to a more accurate representation of the prevalence of dizziness/vertigo and PVD.

This study has two limitations. First, it was conducted at only one primary care clinic. Therefore, its results might not be generalizable to other primary care clinics in Japan. Another limitation is this study’s selection bias. The participants of this study had lifestyle-related diseases. If these are associated with PVD, the incidence found in our study might be inaccurately estimated as being higher than that in the general population. It is known that metabolic syndrome and diabetes mellitus are associated with vestibular dysfunction.\textsuperscript{33,34} We need to investigate the incidence of PVD among different primary care clinics and within the general population in future studies. We will also need to analyze the associations between lifestyle-related diseases and PVD.

**Conclusion**

We reported the incidence of dizziness/vertigo among Japanese primary care clinic patients, which was higher than that usually observed in the general population-based data. Furthermore, we described the incidence of PVD and found it to be a major cause of dizziness/vertigo.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


